The “Great Biotech Reset” is here. Capital is scarce, and the margin for error is zero. Yet, most VCs are still getting blindsided by the same operational failures: flawed trial designs, weak CRO contracts, and founder-operators who can’t scale.
The Problem:
We analyzed 100+ biotech investment memos. The pattern was clear: the “VC Operational Blindspot” is where promising science becomes a portfolio write-down.
The Solution:
So, we built a tool to close that gap. We’ve distilled 20+ years of CRO leadership into a single page.
🎯 Introducing: “The Operational Due Diligence Checklist: 10 Red Flags VCs Miss Before Signing a Term Sheet.”
This isn’t another theoretical framework. It’s the same practical checklist we use in our 4-week, Due-Diligence Sprints for top-tier funds.
Inside, you’ll learn how to spot:
✓ The “Hockey Stick” Runway Model that hides cash burn.
✓ Flawed Clinical Trial Designs that produce unconvincing data.
✓ Weak CRO Contracts with no performance clawbacks.
✓ The “Portfolio Black Box” hiding your asset’s true health.
This checklist is the tactical companion to our widely-shared White Paper, “The Great Biotech Reset.” It’s built for one purpose: to help you identify deal-killing operational flaws before you commit capital.
Ready to de-risk your next investment?
⬇️ DOWNLOAD THE CHECKLIST HERE ⬇️